Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanBlok H5N1 vaccine with and without GLA-SE adjuvant in healthy adults
NCT01147068Phase 2Completed
- Sponsor
- Protein Sciences
- Start
- Jun 2010
- Primary completion
- Oct 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Panblok in Influenza A H5N1 infection (H5N1) (7 arms), sponsored by Protein Sciences. Primary endpoint: Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo at Day 42. Started Jun 2010; status: completed.
02
Drugs
Panblok
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on NCT01147068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147068.